18F FAMT PET can be prognostic marker for pulmonary adenocarcinoma

06/15/2010 | HealthImaging.com

A Japanese study of 88 patients with stage I to IV nonsmall cell lung cancer -- 57 with adenocarcinoma and 31 with squamous cell carcinoma -- who underwent PET before treatment showed that the maximal standardized uptake value of 18F FAMT in adenocarcinoma was lower than that in squamous cell carcinoma, while the use of 18F FDG did not show a difference between the two. PET with 18F FAMT "is a potential prognostic marker in patients with pulmonary adenocarcinoma," the researchers said.

View Full Article in:

HealthImaging.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA